Skip to content
DataLookout
Menu

NCT06298019

Study of KYV-101 Anti-CD19 CAR T Therapy in Adult Dermatomyositis

StatusActive, Not Recruiting
PhasePhase 1
Primary completion (estimated)

At risk: Primary completion moved at least 32 days later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 52 words Show 4 more changesShow less
    • Enrollment closed, study ongoing
    • Primary completion pushed from Apr 2027 to Jun 2027
    • Study completion moved earlier from Apr 2039 to Jul 15, 2027
    • Site details revised at 2 of 2 sites
  2. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Apr 2024 to Aug 2, 2024
    • Study sites: 1 to 2
    v2
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Number of participants experiencing adverse events
Timeframe: 24 weeks

Arms and interventions

Active Intervention with CAR TExperimental

All participants in the trial will receive an infusion of autologous, genetically modified CAR T cells specific for the CD19 antigen

Biologicals: KYV-101

Sites

2 sites in 1 country